Population / Measure of fibrosis / Outcomes / Study
177 patients with known CAD and scar tissue on LGE CMR / LGE size / Cardiac and noncardiac death or nonfatal MI at 1.7years / 40
231 patients with healed MI (>3months after MI) / LGE size, transmurality / All-causemortality at 1.7years / 41
1,148 patients with known or suspected CAD / Presence of LGE / MACE at 2.6years / 42
195patientswithout a known previous MIand signs or symptoms of CAD / Presence of LGE / MACE and cardiac mortality at 1.3years / 43
100 patients with CAD / LGE size / All-cause mortality at 4.8years / 44
44 patients with CMR 10±6days after infarction / Presence of MVO, LGE size / 2year cardiovascular morbidity or mortality / 50
281 patients with acute STEMI and primary angioplasty 4.3days after the acute event / Extent of MVO, LGE size / All-cause mortality, recurrent MI, or congestive HF requiring hospitalization / 51
184 patients within the week after successfully reperfusedfirst acute MI / Presence/ persistent MVO / MACE at 1year / 52
438 patients with STEMI reperfused by primary angioplasty <12h after symptom onset / Presence and extent of late MVO / Death, nonfatalMI, orcongestive HF at 1.6years / 53
208 patients with STEMI undergoing primary angioplasty <12h after symptom onset / Myocardial salvage / MACE at 0.5years / 55
47patients before ICD implantation for primary prevention of SCD / Grey-zone size / Inducibility for monomorphic VT / 56
91patientswith previous MI scheduled for ICD implantation / Grey-zone size / Spontaneous ventricular arrhythmia with subsequent ICD therapy / 58
144 patients with documented CAD and LGE consistent with MI / Grey-zone size / All-cause mortality and cardiovascular mortality at 2.4years / 60
184 patients with DCM / Presence of LGE / Cardiac death, hospitalization for congestive HF, or appropriate ICD discharge at 1.8years / 63
65 NICM patients with a left ventricular ejection fraction≤35% / Presence of LGE / Cardiac death, hospitalization for HF, or ICD discharge at 1.4years / 64
137 patients with nonischaemic DCM / Presence of LGE / VT, ICD intervention, or VF and SCD at 3years / 65
243 patients with HCM / Presence of LGE / All-cause or cardiac mortality at 3years / 69
424 patients with HCM without a history of septal ablation or myectomy / Presence of LGE / SCD or appropriate implanted ICD therapy at 3.6 years / 72
47 patients with suspected cardiac amyloidosis / Presence of LGE / All-cause mortality at 1year / 75
664 patientswithout known previous MI referred for radiofrequency ablation of atrial fibrillation / Presence and size of LGE / All-cause mortality at 3.6years / 83
1,644 patients with systemic hypertension andknownorsuspectedCAD (no previous MI) / Presence and size of LGE / MACE at 2.4years / 84
187 diabetic patients with or without MI / Presence of LGE / MACE at 1.4years / 85
793 patients without amyloidosis or HCM / ECV / All-cause mortality and composite (death, cardiac transplantation, or left ventricular assist device implantation) at 0.8years / 151
231 diabetic patients without amyloidosis / ECV / Mortality or hospitalization for HF at 1.3years / 141
61 patients with HF with preserved ejection fraction without amyloidosis or sarcoidosis / Postcontrast T1 / Hospitalization for HF or cardiac death at 1.5years / 123
101 patients with DCM / Presence of mid-wall LGE / All-cause death or hospitalization at 1.8years / 156
Abbreviations:CAD, coronary artery disease; CMR, cardiac magnetic resonance; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; HF, heart failure; ICD, implantable cardioverter defibrillator; LGE, late gadolinium enhancement; MACE, major adverse cardiac event; MI, myocardial infarction; MVO, microvascular obstruction; SCD, sudden cardiac death; STEMI, ST-segment elevation myocardial infarction; VF, ventricular fibrillation; VT, ventricular tachycardia.
Supplementary reference
156.Assomull, R.G. etal.Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J. Am. Coll. Cardiol.48, 1977–1985 (2006).